Clinical impact of H-Y alloimmunity

Immunologic Research

Volumn 58, Issue 2-3, 2014, Pages 249-258

  Popli, Rakesh ^a   Sahaf, Bita ^a   Nakasone, Hideki ^a   Lee, Joyce Yeuk Yu ^a   Miklos, David B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alloimmunity; Graft rejection; Graft versus host disease; H Y antigen; Kidney transplantation; Pregnancy complications

Indexed keywords

HY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; ALLOANTIBODY; H-Y ANTIBODY;

ALLOIMMUNITY; ANTIBODY DETECTION; B LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; DNA SEQUENCE; GENDER; GRAFT RECIPIENT; HEMATOPOIETIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; ORGAN DONOR; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RELAPSE; REVIEW; SPONTANEOUS ABORTION; X CHROMOSOME; Y CHROMOSOME; ANIMAL; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOLOGY; MALE; ORGAN TRANSPLANTATION; PREGNANCY; RECURRENT ABORTION; SEX DIFFERENCE; T LYMPHOCYTE;

ABORTION, HABITUAL; ANIMALS; B-LYMPHOCYTES; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; H-Y ANTIGEN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; ISOANTIBODIES; MALE; ORGAN TRANSPLANTATION; PREGNANCY; SEX FACTORS; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY;

EID: 84901405391     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-014-8514-3     Document Type: Review

References (104)

1. Brickner AG. Mechanisms of minor histocompatibility antigen immunogenicity: the role of infinitesimal versus structurally profound polymorphisms. Immunol Res. 2006;36(1-3):33-41. (Pubitemid 46398606)
2. Miklos DB, Kim HT, Zorn E, et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood. 2004;103(1):353-9. (Pubitemid 38035116)
3. Arai S, Jagasia M, Storer B, et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood. 2011;118(15):4242-9.
4. Carlens S, Ringdén O, Remberger M, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant. 1998;22(8):755-61. (Pubitemid 28488318)
5. Zorn E, Miklos DB, Floyd BH, et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med. 2004;199(8):1133-42. (Pubitemid 38619909)
6. Gratwohl A, Döhler B, Stern M, Opelz G. H-Y as a minor histocompatibility antigen in kidney transplantation: a retrospective cohort study. Lancet. 2008;372(9632):49-53. (Pubitemid 351902262)
7. Tan JC, Wadia PP, Coram M, et al. H-Y antibody development associates with acute rejection in female patients with male kidney transplants. Transplantation. 2008;86(1):75-81.
8. Nielsen HS. Secondary recurrent miscarriage and H-Y immunity. Hum Reprod Update. 2011;17(4):558-74.
9. Eichwald EJ, Silmser CR. Skin. Transplant Bull. 1955;2:148-9.
10. Eichwald EJ, Silmser CR, Wheeler N. The genetics of skin grafting. Ann NY Acad Sci. 1957;64(5):737-40.
11. Lustgraaf EC, Fuson RB, Eichwald EJ. Sex tolerance and split tolerance. Transplant Bull. 1960;26:145-50.
12. Eichwald EJ, Lustgraaf EC, Weissman I, Strainer M. Attempts to demonstrate sex-linked histocompatibility genes. Transplant Bull. 1958;5(4):387-8.
13. Billingham RE, Silvers WK. Induction of tolerance of skin isografts from male donors in female mice. Science. 1958;128(3327):780-1.
14. Billingham RE, Silvers WK. Studies on tolerance of the Y chromosome antigen in mice. J Immunol. 1960;85:14-26.
15. Carlens S, Ringdén O, Remberger M, et al. Factors affecting risk of relapse and leukemia-free survival in HLA-identical sibling marrow transplant recipients with leukemia. Transplant Proc. 1997;29(7):3147-9.
16. Remberger M, Kumlien G, Aschan J, et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8(12):674-82. (Pubitemid 36097807)
17. Remberger M, Mattsson J, Hassan Z, et al. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study. Bone Marrow Transplant. 2008;41(4):399-405. (Pubitemid 351330736)
18. Spierings E, Kim YH, Hendriks M, et al. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(8):1244-53.
19. Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood. 2004;103(1):347-52. (Pubitemid 38029959)
20. Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98(7):2043-51.
21. Loren AW, Bunin GR, Boudreau C, et al. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12(7):758-69. (Pubitemid 43899412)
22. Goulmy E, Termijtelen A, Bradley BA, van Rood JJ. Y-antigen killing by T cells of women is restricted by HLA. Nature. 1977;266(5602):544-5. (Pubitemid 8079243)
23. Goulmy E, Bradley BA, Lansbergen Q, van Rood JJ. The importance of H-Y incompatibility in human organ transplantation. Transplantation. 1978;25(6):315-9. (Pubitemid 9094887)
24. Goulmy E, Gratama JW, Blokland E, Zwaan FE, van Rood JJ. A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease. Nature. 1983;302(5904):159-61. (Pubitemid 13160997)
25. Goulmy E, van Leeuwen A, Blokland E, Sachs ES, Geraedts JP. The recognition of abnormal sex chromosome constitution by HLA-restricted anti-H-Y cytotoxic T cells and antibody. Immunogenetics. 1983;17(5):523-31. (Pubitemid 13130107)
26. Goulmy E, Schipper R, Pool J, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med. 1996;334(5):281-5. (Pubitemid 26033083)
27. Goulmy E. Human minor histocompatibility antigens. Curr Opin Immunol. 1996;8(1):75-81. (Pubitemid 26105823)
28. Wang W, Meadows LR, den Haan JM, et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science. 1995;269(5230):1588-90.
29. Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med. 1999;5(7):839-42. (Pubitemid 29318622)
30. Tilford CA, Kuroda-Kawaguchi T, Skaletsky H, et al. A physical map of the human Y chromosome. Nature. 2001;409(6822):943-5. (Pubitemid 32165350)
31. Skaletsky H, Kuroda-Kawaguchi T, Minx PJ, et al. The malespecific region of the human Y chromosome is a mosaic of discrete sequence classes. Nature. 2003;423(6942):825-37. (Pubitemid 36781267)
32. Lahn BT, Page DC. Functional coherence of the human Y chromosome. Science. 1997;278(5338):675-80. (Pubitemid 27464964)
33. Eljaafari A, Yuruker O, Ferrand C, et al. Isolation of human CD4/CD8 double-positive, graft-versus-host disease-protective, minor histocompatibility antigen-specific regulatory T cells and of a novel HLA-DR7-restricted HY-specific CD4 clone. J Immunol. 2013;190(1):184-94.
34. Warren EH, Gavin MA, Simpson E, et al. The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J Immunol. 2000;164(5):2807-14. (Pubitemid 30115516)
35. Pennisi E. Long-sought H-Y antigen found. Science. 1995;269(5230):1515-6.
36. Vogt MH, de Paus RA, Voogt PJ, Willemze R, Falkenburg JH. DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. Blood. 2000;95(3):1100-5. (Pubitemid 30062737)
37. Vogt MH, Goulmy E, Kloosterboer FM, et al. UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. Blood. 2000;96(9):3126-32.
38. Vogt MH, van den Muijsenberg JW, Goulmy E, et al. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood. 2002;99(8):3027-32. (Pubitemid 34525395)
39. Pierce RA, Field ED, den Haan JM, et al. Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. J Immunol. 1999;163(12):6360-4.
40. Rosinski KV, Fujii N, Mito JK, et al. DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells. Blood. 2008;111(9):4817-26.
41. Spierings E, Vermeulen CJ, Vogt MH, et al. Identification of HLA class II-restricted H-Y-specific T-helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation. Lancet. 2003;362(9384):610-5. (Pubitemid 37013301)
42. Torikai H, Akatsuka Y, Miyazaki M, et al. A novel HLAA* 3303-restricted minor histocompatibility antigen encoded by an unconventional open reading frame of human TMSB4Y gene. J Immunol. 2004;173(11):7046-54. (Pubitemid 39541094)
43. Ofran Y, Kim HT, Brusic V, et al. Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. Clin Cancer Res. 2010;16(5):1642-51.
44. Ivanov R, Aarts T, Hol S, et al. Identification of a 40S ribosomal protein S4-derived H-Y epitope able to elicit a lymphoblastspecific cytotoxic T lymphocyte response. Clin Cancer Res. 2005;11(5):1694-703. (Pubitemid 40471830)
45. Mortensen BK, Rasmussen AH, Larsen ME, et al. Identification of a novel UTY-encoded minor histocompatibility antigen. Scand J Immunol. 2012;76(2):141-50.
46. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus- host disease and disease remission. Blood. 2005;105(7):2973-8. (Pubitemid 40446295)
47. Porcheray F, Miklos DB, Floyd BH, et al. Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation. Transplantation. 2011;92(3):359-65.
48. Veerapathran A, Pidala J, Beato F, et al. Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease. Blood. 2013;122(13):2251-61.
49. Stern M, Brand R, de Witte T, et al. Female-versus-male alloreactivity as a model for minor histocompatibility antigens in hematopoietic stem cell transplantation. Am J Transplant. 2008;8(10):2149-57.
50. Markiewicz M, Siekiera U, Karolczyk A, et al. Immunogenic disparities of 11 minor histocompatibility antigens (mHAs) in HLA-matched unrelated allogeneic hematopoietic SCT. Bone Marrow Transplant. 2009;43(4):293-300.
51. Markiewicz M, Siekiera U, Dzierzak-Mietla M, Zielinska P, Kyrcz-Krzemien S. The impact of H-Y mismatches on results of HLA-matched unrelated allogeneic hematopoietic stem cell transplantation. Transplant Proc. 2010;42(8):3297-300.
52. Li L, Wadia P, Chen R, et al. Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome" measures. Proc Natl Acad Sci USA. 2009;106(11):4148-53.
53. Wadia PP, Sahaf B, Miklos DB. Recombinant antigen microarrays for serum/plasma antibody detection. Methods Mol Biol. 2011;723:81-104.
54. Sahaf B, Yang Y, Arai S, Herzenberg LA, Miklos DB. H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease. Proc Natl Acad Sci USA. 2013;110(8):3005-10.
55. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108(2):756-62. (Pubitemid 44061381)
56. Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 2007;40(3):273-7. (Pubitemid 47108472)
57. Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2009;15(9):1005-13.
58. Arai S, Sahaf B, Narasimhan B, et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood. 2012;119(25):6145-54.
59. Cutler C, Kim HT, Bindra B, et al. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood. 2013;122(8):1510-7.
60. Dzierzak-Mietla M, Markiewicz M, Siekiera U, et al. Occurrence and impact of minor histocompatibility antigens' disparities on outcomes of hematopoietic stem cell transplantation from HLA-matched sibling donors. Bone Marrow Res. 2012;2012:257086.
61. Hobo W, Broen K, van der Velden WJ, et al. Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(2):274-82.
62. Verdijk RM, Kloosterman A, Pool J, et al. Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy. Blood. 2004;103(5):1961-4. (Pubitemid 38268999)
63. James E, Chai JG, Dewchand H, Macchiarulo E, Dazzi F, Simpson E. Multiparity induces priming to male-specific minor histocompatibility antigen, HY, in mice and humans. Blood. 2003;102(1):388-93. (Pubitemid 36759681)
64. Piper KP, McLarnon A, Arrazi J, et al. Functional HY-specific CD8+ T cells are found in a high proportion of women following pregnancy with a male fetus. Biol Reprod. 2007;76(1):96-101. (Pubitemid 46013452)
65. Takemoto SK, Terasaki PI, Gjertson DW, Cecka JM. Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med. 2000;343(15):1078-84.
66. Cecka JM, Zhang Q, Reed EF. Preformed cytotoxic antibodies in potential allograft recipients: recent data. Hum Immunol. 2005;66(4):343-9. (Pubitemid 40615788)
67. Clatworthy MR. Targeting B cells and antibody in transplantation. Am J Transplant. 2011;11(7):1359-67.
68. Jordan SC, Kahwaji J, Toyoda M, Vo A. B-cell immunotherapeutics: emerging roles in solid organ transplantation. Curr Opin Organ Transplant. 2011;16(4):416-24.
69. Platt JL, Cascalho M. Donor specific antibodies after transplantation. Pediatr Transplant. 2011;15(7):686-90.
70. van Rood JJ, van Leeuwen A, Persijn GG, et al. Role of the HLA system in transplantation. HLA compatibility in clinical transplantation. Transplant Proc. 1977;9(1):459-67.
71. Bestard O, Cruzado JM, la Franquesa M, Grinyó JM. Biomarkers in renal transplantation. Curr Opin Organ Transplant. 2010;15(4):467-73.
72. Terasaki PI. Deduction of the fraction of immunologic and nonimmunologic failure in cadaver donor transplants. Clin Transpl. 2003;449-452.
73. Cecka JM. The OPTN/UNOS Renal Transplant Registry. Clin Transpl. 2005;1-16.
74. Stegall MD, Chedid MF, Cornell LD. The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol. 2012;8(11):670-8.
75. Cornell LD. Renal allograft pathology in the sensitized patient. Curr Opin Organ Transplant. 2013;18(3):327-36.
76. Haas M. Pathology of C4d-negative antibody-mediated rejection in renal allografts. Curr Opin Organ Transplant. 2013;18(3):319-26.
77. Kim SJ, Gill JS. H-Y incompatibility predicts short-term outcomes for kidney transplant recipients. J Am Soc Nephrol. 2009;20(9):2025-33.
78. Wagner S. H-Y antigen in kidney transplant: Does gender matter? Gend Med. 2012;9(5):387-8.
79. Pfeffer PF, Thorsby E. HLA-restricted cytotoxicity against male-specific (H-Y) antigen after acute rejection of an HLA-identical sibling kidney: clonal distribution of the cytotoxic cells. Transplantation. 1982;33(1):52-6. (Pubitemid 12162771)
80. Keith DS, Patrie JT. H-Y antigen incompatibility not associated with adverse immunologic graft outcomes: deceased donor pair analysis of the OPTN database. J Transplant. 2011;2011:148457.
81. Khush KK, Kubo JT, Desai M. Influence of donor and recipient sex mismatch on heart transplant outcomes: analysis of the International Society for Heart and Lung Transplantation Registry. J Heart Lung Transplant. 2012;31(5):459-66.
82. Kittleson MM, Patel JK, Moriguchi JD, et al. Heart transplant recipients supported with extracorporeal membrane oxygenation: outcomes from a single-center experience. J Heart Lung Transplant. 2011;30(11):1250-6.
83. Kfoury AG, Hammond ME, Snow GL, et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. J Heart Lung Transplant. 2009;28(8):781-4.
84. Welp H, Spieker T, Erren M, Scheld HH, Baba HA, Stypmann J. Sex mismatch in heart transplantation is associated with increased number of severe rejection episodes and shorter longterm survival. Transplant Proc. 2009;41(6):2579-84.
85. Candinas D, Gunson BK, Nightingale P, Hubscher S, McMaster P, Neuberger JM. Sex mismatch as a risk factor for chronic rejection of liver allografts. Lancet. 1995;346(8983):1117-21.
86. Thellin O, Heinen E. Pregnancy and the immune system: between tolerance and rejection. Toxicology. 2003;185(3):179-84. (Pubitemid 36173734)
87. Mor G, Cardenas I, Abrahams V, Guller S. Inflammation and pregnancy: the role of the immune system at the implantation site. Ann NY Acad Sci. 2011;1221:80-7.
88. Christiansen OB, Steffensen R, Nielsen HS. The impact of anti- HY responses on outcome in current and subsequent pregnancies of patients with recurrent pregnancy losses. J Reprod Immunol. 2010;85(1):9-14.
89. Christiansen OB, Pedersen B, Nielsen HS, Nybo Andersen AM. Impact of the sex of first child on the prognosis in secondary recurrent miscarriage. Hum Reprod. 2004;19(12):2946-51. (Pubitemid 40028971)
90. Christiansen OB, Steffensen R, Nielsen HS. Anti-HY responses in pregnancy disorders. Am J Reprod Immunol. 2011;66(Suppl 1):93-100.
91. Nielsen HS, Steffensen R, Lund M, et al. Frequency and impact of obstetric complications prior and subsequent to unexplained secondary recurrent miscarriage. Hum Reprod. 2010;25(6):1543-52.
92. Christiansen OB. Reproductive immunology. Mol Immunol. 2013;55(1):8-15.
93. Khosrotehrani K, Bianchi DW. Multi-lineage potential of fetal cells in maternal tissue: a legacy in reverse. J Cell Sci. 2005;118(Pt 8):1559-63. (Pubitemid 40691884)
94. Linscheid C, Petroff MG. Minor histocompatibility antigens and the maternal immune response to the fetus during pregnancy. Am J Reprod Immunol. 2013;69(4):304-14.
95. Nielsen HS, Mogensen M, Steffensen R, Kruse C, Christiansen OB. Indications of anti-HY immunity in recurrent placental abruption. J Reprod Immunol. 2007;75(1):63-9. (Pubitemid 47081189)
96. Nielsen HS, Steffensen R, Varming K, et al. Association of HYrestricting HLA class II alleles with pregnancy outcome in patients with recurrent miscarriage subsequent to a firstborn boy. Hum Mol Genet. 2009;18(9):1684-91.
97. Nielsen HS, Wu F, Aghai Z, et al. H-Y antibody titers are increased in unexplained secondary recurrent miscarriage patients and associated with low male: female ratio in subsequent live births. Hum Reprod. 2010;25(11):2745-52.
98. Christiansen OB, Pedersen B, Rosgaard A, Husth M. A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage. Hum Reprod. 2002;17(3):809-16. (Pubitemid 34232457)
99. Christiansen OB, Nielsen HS, Pedersen B. Active or passive immunization in unexplained recurrent miscarriage. J Reprod Immunol. 2004;62(1-2):41-52. (Pubitemid 38993269)
100. Hutton B, Sharma R, Fergusson D, et al. Use of intravenous immunoglobulin for treatment of recurrent miscarriage: a systematic review. BJOG. 2007;114(2):134-42. (Pubitemid 46089441)
101. Stephenson MD, Kutteh WH, Purkiss S, et al. Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial. Hum Reprod. 2010;25(9):2203-9.
102. Somerset DA, Zheng Y, Kilby MD, Sansom DM, Drayson MT. Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology. 2004;112(1):38-43. (Pubitemid 38609820)
103. van Halteren AG, Jankowska-Gan E, Joosten A, et al. Naturally acquired tolerance and sensitization to minor histocompatibility antigens in healthy family members. Blood. 2009;114(11):2263-72.
104. Kahn DA, Baltimore D. Pregnancy induces a fetal antigenspecific maternal T regulatory cell response that contributes to tolerance. Proc Natl Acad Sci USA. 2010;107(20):9299-304.